Integra LifeSciences (IART) Reports In-Line Q3 EPS, Revenues Miss; Raises FY18 Revenue Outlook, Maintains FY18 EPS Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. SPY
4. META
5. MU
6. NVDA
7. BLZE
8. IBM
9. PRIM
10. ACN

Go back to Integra LifeSciences (IART) Reports In-Line Q3 EPS, Revenues Miss; Raises FY18 Revenue Outlook, Maintains FY18 EPS Guidance

Integra LifeSciences Reports Third Quarter 2018 Financial Results

October 31, 2018 6:00 AM EDT

Revenue Increased 31.2% to $365.9 million; Organic Revenue Increased 6.2%

Reported EPS of $0.15; Adjusted EPS of $0.59

Revises Full-Year 2018 Revenue Guidance to $1.467 Billion to $1.472 Billion and Organic Revenue Growth to Approximately 4%

PLAINSBORO, N.J., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30,... More